Results 191 to 200 of about 42,124 (246)

Dexamethasone-tamoxifen combination exerts synergistic therapeutic effects in tamoxifen-resistance breast cancer cells. [PDF]

Biosci Rep
Gaballah AI, Elsherbiny AA, Sharaky M, Hamed NO, Raslan NA, Almilaibary A, Fayyad RMA, Ousman MS, Hamdan AME, Fahim SA.   +9 more
europepmc   +1 more source

Reversal of tamoxifen resistance by artemisinin in ER+ breast cancer: bioinformatics analysis and experimental validation. [PDF]

Oncol Res
Zhuo Z, Zhang D, Lu W, Wu X, Cui Y, Zhang W, Zhang M.   +6 more
europepmc   +1 more source

Correlating NAD(P)H lifetime shifts to tamoxifen resistance in breast cancer cells: A metabolic screening study with time-resolved flow cytometry. [PDF]

J Innov Opt Health Sci
Valentino S, Ortega-Sandoval K, Houston KD, Houston JP.   +3 more
europepmc   +1 more source

MCL restrained ROS/AKT/ASAH1 pathway to therapy tamoxifen resistance breast cancer by stabilizing NRF2. [PDF]

Cell Prolif
Han X, Zhang Y, Li Y, Lin Z, Fu Z, Wang C, Zhang S, Shao D, Li C.   +8 more
europepmc   +1 more source

Targeting LINC00152 activates cAMP/Ca²⁺/ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer. [PDF]

Cell Death Dis
Saatci O, Alam R, Huynh-Dam KT, Isik A, Uner M, Belder N, Ersan PG, Tokat UM, Ulukan B, Cetin M, Calisir K, Gedik ME, Bal H, Sener Sahin O, Riazalhosseini Y, Thieffry D, Gautheret D, Ogretmen B, Aksoy S, Uner A, Akyol A, Sahin O.   +21 more
europepmc   +1 more source

Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance. [PDF]

Breast Cancer Res
Song T, Zhang H, Zhao Q, Hu Z, Wang Z, Song Y, Zhang Z.   +6 more
europepmc   +1 more source

Cystathionine-γ-lyase contributes to tamoxifen resistance, and the compound I194496 alleviates this effect by inhibiting the PPARγ/ACSL1/STAT3 signalling pathway in oestrogen receptor-positive breast cancer. [PDF]

Sci Rep
Fu H, Han X, Guo W, Zhao X, Yu C, Zhao W, Feng S, Wang J, Zhang Z, Lei K, Li M, Wang T.   +11 more
europepmc   +1 more source

Correction: Tsoi et al. Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer. Life 2022, 12, 93. [PDF]

Life (Basel)
Tsoi H, Shi L, Leung MH, Man EPS, So ZQ, Chan WL, Khoo US.   +6 more
europepmc   +1 more source

[Corrigendum] Long non‑coding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. [PDF]

Int J Oncol
Li Z, Yu D, Li H, Lv Y, Li S.
europepmc   +1 more source

Tamoxifen Resistance in Breast Cancer

Biomolecules and Therapeutics, 2012
Tamoxifen is a central component of the treatment of estrogen receptor (ER)-positive breast cancer as a partial agonist of ER. It has been clinically used for the last 30 years and is currently available as a chemopreventive agent in women with high risk for breast cancer.
Minsun Chang
exaly   +4 more sources